CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensiti
Tag: Cerus
Cerus Endovascular Receives CE Mark Approval for its CerusEndo MC 021 Microcatheter
Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020 FREMONT, Calif. and OXFORD, United Kingdom, July 28, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its […]
Cerus Endovascular Successfully Completes Series B Financing and Receives U.S. FDA Approval for its First Microcatheter
Completion of Series B Financing Round Strengthens and Readies the Company for Commercialization of Two Products During the Second Quarter of 2020 FREMONT, Calif. and OXFORD, England, Feb. 21, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that […]
